The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States

Ajay Sheshadria Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Naomi C. Sacksb Precision Health Economics and Outcomes Research, Boston, MA, USA;c Tufts University School of Medicine, Boston, MA, USACorrespondence[email protected]

https://orcid.org/0000-0003-0038-4385

Bridget Healeyb Precision Health Economics and Outcomes Research, Boston, MA, USA

Phil Cyrb Precision Health Economics and Outcomes Research, Boston, MA, USA;d College of Health and Human Services, University of North Carolina, Charlotte, NC, USA

Gerhard Boernere Breath Therapeutics, GmbH, a Zambon company, Munich, Germany;f Zambon Group, Bresso, Italy

Howard J. Huangg Division of Pulmonary, Critical Care and Sleep Medicine, Houston Methodist Hospital, Houston, TX, USA

The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date